keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation

keyword
https://www.readbyqxmd.com/read/28628013/modulation-of-antitumor-immune-response-in-mouse-prostate-cancer-model
#1
N Mitskevich, T Tsertsvadze, K Mchedlishvili, K Matchavariani, G Guruli
Aim of study - prostate cancer is second most common cancer in men worldwide, and fifth leading cause of death from cancer in men (6.6% of the total men deaths). Unfortunately, once cancer spreads outside of prostate, it becomes incurable. Androgen deprivation can provide some relief, but resistance will develop eventually, and at that time no effective treatment options are left to the patient. Therefore, the search of alternative treatment modalities is paramount. In this article we evaluated the role of epigenetic modifier 5-azacitidine (5-AzaC) and immunomodulator - Lenalidomide and their possible impact on the immune response in the murine prostate cancer model...
May 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28626107/-molecular-basis-for-prostate-carcinogenesis
#2
Fangzhi Chen, Xiaokun Zhao
Prostate cancer is the most prevalent male urogenital malignancy. Androgen deprivation therapy is the principal method for initial treatment for the patients, but the majority of them will eventually develop progressive disease, a status called castration-resistant prostate carcinoma. Lots of susceptibility genes, tumor suppressor genes and oncogenes, and their variations relevant to the occurrence and development of prostate cancer have been revealed by the studies of molecular oncology. These findings on the molecular basis of prostate carcinogenesis will further improve the strategies on prevention, diagnosis and clinical management for prostate carcinoma...
May 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28622770/intensity-modulated-radiation-therapy-from-70gy-to-80gy-in-prostate-cancer-six-year-outcomes-and-predictors-of-late-toxicity
#3
Maria Jolnerovski, Julia Salleron, Véronique Beckendorf, Didier Peiffert, Anne-Sophie Baumann, Valérie Bernier, Sandrine Huger, Vincent Marchesi, Ciprian Chira
OBJECTIVE: To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS). METHODS: A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46...
June 16, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28614061/a-genetic-variant-in-slc28a3-rs56350726-is-associated-with-progression-to-castration-resistant-prostate-cancer-in-a-korean-population-with-metastatic-prostate-cancer
#4
Jung Ku Jo, Jong Jin Oh, Yong Tae Kim, Hong Sang Moon, Hong Yong Choi, Seunghyun Park, Jin-Nyoung Ho, Sungroh Yoon, Hae Young Park, Seok-Soo Byun
BACKGROUND: Genetic variation which related with progression to castration-resistant prostate cancer (CRPC) during androgen-deprivation therapy (ADT) has not been elucidated in patients with metastatic prostate cancer (mPCa). Therefore, we assessed the association between genetic variants in mPCa and progression to CRPC. RESULTS: Analysis of exome genotypes revealed that 42 SNPs were significantly associated with mPCa. The top five polymorphisms were statistically significantly associated with metastatic disease...
May 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28610779/survival-and-complications-following-surgery-and-radiation-for-localized-prostate-cancer-an-international-collaborative-review
#5
REVIEW
Christopher J D Wallis, Adam Glaser, Jim C Hu, Hartwig Huland, Nathan Lawrentschuk, Daniel Moon, Declan G Murphy, Paul L Nguyen, Matthew J Resnick, Robert K Nam
BACKGROUND: Evaluation of treatment options for localized prostate cancer (PCa) remains among the highest priorities for comparative effectiveness research. Surgery and radiotherapy (RT) are the two interventions most commonly used. OBJECTIVE: To provide a critical narrative review of evidence of the comparative effectiveness and harms of surgery and RT in the treatment of localized PCa. EVIDENCE ACQUISITION: A collaborative critical narrative review of the literature was conducted...
June 10, 2017: European Urology
https://www.readbyqxmd.com/read/28609769/prediction-of-time-to-castration-resistant-prostate-cancer-using-bone-scan-index-in-men-with-metastatic-hormone-sensitive-prostate-cancer
#6
Yasuhide Miyoshi, Shuko Yoneyama, Takashi Kawahara, Yusuke Hattori, Jun-Ichi Teranishi, Jun-Ichi Ohta, Shigeo Takebayashi, Yumiko Yokomizo, Narihiko Hayashi, Hiroji Uemura
INTRODUCTION: We evaluated bone scan index (BSI) as a predictive biomarker for time to castration-resistant prostate cancer (CRPC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). MATERIALS AND METHODS: We identified 85 consecutive mHSPC patients treated with first-line androgen deprivation therapy. We analyzed the correlations between time to CRPC and clinicopathological characteristics, including age, prostate-specific antigen (PSA) level, Gleason score, clinical TNM stage, hemoglobin, lactate dehydrogenase, C-reactive protein, and BSI...
June 14, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28606220/current-and-future-strategies-for-the-nutritional-management-of-cardiometabolic-complications-of-androgen-deprivation-therapy-for-prostate-cancer
#7
Lauren Turner, Karen Poole, Sara Faithfull, Bruce A Griffin
Androgen deprivation therapy (ADT) is used widely as part of a combined modality for the treatment of prostate cancer. However, ADT has also been associated with the development of cardiometabolic complications that can increase mortality from cardiovascular events. There is emerging evidence to suggest that ADT-related cardiometabolic risk can be mitigated by diet and lifestyle modification. While the clinical focus for a nutritional approach for achieving this effect is unclear, it may depend upon the timely assessment and targeting of dietary changes to the specific risk phenotype of the patient...
June 13, 2017: Nutrition Research Reviews
https://www.readbyqxmd.com/read/28604629/androgen-receptor-dependent-and-independent-mechanisms-involved-in-prostate-cancer-therapy-resistance
#8
REVIEW
Daniel J Crona, Young E Whang
Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling is critically required for CRPC. A new generation of medications targeting AR, such as abiraterone and enzalutamide, has improved survival of metastatic CRPC (mCRPC) patients. However, a significant proportion of patients presents with primary resistance to these agents, and in the remainder, secondary resistance will invariably develop, which makes mCRPC the lethal form of the disease...
June 12, 2017: Cancers
https://www.readbyqxmd.com/read/28603917/a-rare-castration-resistant-progenitor-cell-population-is-highly-enriched-in-pten-null-prostate-tumors
#9
Lucila Sackmann Sala, Florence Boutillon, Giulia Menara, Andréa De Goyon-Pélard, Mylène Leprévost, Julie Codzamanian, Natalie Lister, Jan Pencik, Ashlee Clark, Nicolas Cagnard, Christine Bole-Feysot, Richard Moriggl, Gail P Risbridger, Renea A Taylor, Lukas Kenner, Jacques-Emmanuel Guidotti, Vincent Goffin
Castration-resistant prostate cancer is a lethal disease. The cell type(s) that survive androgen-deprivation remain poorly described despite global efforts to understand the various mechanisms of therapy resistance. We recently identified in wild-type (WT) mouse prostates a rare population of luminal progenitor cells that we called LSC(med) according to their FACS profile (Lin(-) /Sca-1(+) /CD49f(med) ). Here we investigated the prevalence and castration-resistance of LSC(med) in various mouse models of prostate tumorigenesis (Pb-PRL, Pten(pc-/-) , Hi-Myc mice)...
June 12, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28599663/salvage-robotic-sbrt-for-local-prostate-cancer-recurrence-after-radiotherapy-preliminary-results-of-the-oscar-lambret-center
#10
Thomas Leroy, Thomas Lacornerie, Emilie Bogart, Philippe Nickers, Eric Lartigau, David Pasquier
BACKGROUND: Currently, there is no standard option for local salvage treatment for local prostate cancer recurrence after radiotherapy. Our objective was to investigate the feasibility and efficiency of Robotic Stereotactic Body Radiation Therapy (SBRT) in this clinical setting. METHODS/MATERIALS: We retrospectively reviewed patients who were treated at our institution with SBRT for local prostate cancer recurrence after External Beam Radiation Therapy (EBRT) or brachytherapy...
June 9, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28599438/androgen-deprivation-therapy-has-no-effect-on-pim-1-expression-in-a-mouse-model-of-prostate-cancer
#11
Jiang Wang, Gang Li, Bo Li, Hualin Song, Zhiqun Shang, Ning Jiang, Yuanjie Niu
The aim of the present study was to observe the dynamic changes of proto-oncogene, serine/threonine kinase, Pim-1 at the gene and protein level in a mouse model of prostate cancer following surgical castration. Using LNCaP cells to establish a subcutaneous xenograft model and orthotopic prostate cancer BALB/c nude mouse models, the xenograft models were divided into an androgen-dependent prostate cancer group (ADPC), an androgen deprivation therapy (ADT) group and an androgen independent prostate cancer (AIPC) group...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28598810/the-prevention-of-fragility-fractures-in-patients-with-non-metastatic-prostate-cancer-a-position-statement-by-the-international-osteoporosis-foundation
#12
REVIEW
Luisella Cianferotti, Francesco Bertoldo, Marco Carini, John A Kanis, Alberto Lapini, Nicola Longo, Giuseppe Martorana, Vincenzo Mirone, Jean-Yves Reginster, Rene Rizzoli, Maria Luisa Brandi
Androgen deprivation therapy is commonly employed for the treatment of non-metastatic prostate cancer as primary or adjuvant treatment. The skeleton is greatly compromised in men with prostate cancer during androgen deprivation therapy because of the lack of androgens and estrogens, which are trophic factors for bone. Men receiving androgen deprivation therapy sustain variable degrees of bone loss with an increased risk of fragility fractures. Several bone antiresorptive agents have been tested in randomized controlled trials in these patients...
May 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28598253/androgen-receptor-and-mir-206-regulation-in-prostate-cancer
#13
Fu Yee Gua, Brian D Adams
In the United States, prostate cancer is the second leading cause of cancer related deaths among men with an approximately 220,000 patients diagnosed with the disease in 2015. Prostate cancer is a hormone-driven tumor, and a common therapy is androgen-deprivation therapy (ADT) which involves anti-androgen treatments and/or castration therapy. Understanding the molecular basis for androgen-independent tumors is crucial towards developing new therapies for these patients. Understanding how androgen receptor itself functions, is an important first step in elucidating this process...
June 9, 2017: Transcription
https://www.readbyqxmd.com/read/28596572/inhibition-of-androgen-receptor-promotes-cxc-chemokine-receptor-7-mediated-prostate-cancer-cell-survival
#14
James J Hoy, Georgios Kallifatidis, Diandra K Smith, Bal L Lokeshwar
The atypical C-X-C chemokine receptor 7 (CXCR7) has been implicated in supporting aggressive cancer phenotypes in several cancers including prostate cancer. However, the mechanisms driving overexpression of this receptor in cancer are poorly understood. This study investigates the role of androgen receptor (AR) in regulating CXCR7. Androgen deprivation or AR inhibition significantly increased CXCR7 expression in androgen-responsive prostate cancer cell lines, which was accompanied by enhanced epidermal growth factor receptor (EGFR)-mediated mitogenic signaling, promoting tumor cell survival through an androgen-independent signaling program...
June 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28596498/somatic-mutations-in-salivary-duct-carcinoma-and-potential-therapeutic-targets
#15
Timothy K Khoo, Bing Yu, Joel A Smith, Angus J Clarke, Peter P Luk, Christina I Selinger, Kate L Mahon, Spiridoula Kraitsek, Carsten Palme, Michael J Boyer, Marcel E Dinger, Mark J Cowley, Sandra A O'Toole, Jonathan R Clark, Ruta Gupta
BACKGROUND: Salivary duct carcinomas (SDCa) are rare highly aggressive malignancies. Most patients die from distant metastatic disease within three years of diagnosis. There are limited therapeutic options for disseminated disease. RESULTS: 11 cases showed androgen receptor expression and 6 cases showed HER2 amplification. 6 Somatic mutations with additional available targeted therapies were identified: EGFR (p.G721A: Gefitinib), PDGFRA (p.H845Y: Imatinib and Crenolanib), PIK3CA (p...
May 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28589901/resveratrol-enhances-polyubiquitination-mediated-arv7-degradation-in-prostate-cancer-cells
#16
Sarah Wilson, Lucia Cavero, Dali Tong, Qiuli Liu, Kyla Geary, Nicholas Talamonti, Jing Xu, Junjiang Fu, Jun Jiang, Dianzheng Zhang
Although androgen deprivation therapy (ADT) serves as the primary treatment option for localized or metastatic prostate cancer, most cases eventually develop into castration-resistant prostate cancer (CRPC). However, androgen receptor (AR) continues to be functional in CRPC through various mechanisms, including the development of AR splicing variants, especially ARV7. Since it lacks the ligand binding domain but retains the intact DNA binding domain, ARV7 is constitutively active, which makes ARV7-positive prostate cancer responsive to neither abiraterone nor enzalutamide...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28589396/the-use-of-hormonal-therapy-to-augment-radiation-therapy-in-prostate-cancer-an-update
#17
REVIEW
Greg Kauffmann, Stanley L Liauw
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician...
July 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28588730/conversion-to-monotherapy-with-luteinizing-hormone-releasing-hormone-agonist-or-orchiectomy-after-reaching-psa-nadir-following-maximal-androgen-blockade-is-able-to-prolong-progression-free-survival-in-patients-with-metastatic-prostate-cancer-a-propensity-score
#18
Gyeong Eun Min, Hanjong Ahn
The present study evaluated androgen deprivation methods to determine the approach that most improves the progression-free survival (PFS) of patients with metastatic prostate cancer. Patients had received continuous maximal androgen blockade (MAB) or monotherapy [luteinizing-hormone releasing hormone (LHRH) agonist or orchiectomy] following the reaching of the prostate specific antigen (PSA) nadir. The medical records of 293 patients who received MAB following a diagnosis of metastatic prostate cancer were retrospectively reviewed...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28581399/cognitive-function-in-patients-with-prostate-cancer-receiving-luteinizing-hormone-releasing-hormone-analogues-a-prospective-observational-multicenter-study
#19
Juan Morote, Ángel José Tabernero, José Luis Álvarez Ossorio, Juan Pablo Ciria, José Luis Domínguez-Escrig, Fernando Vázquez, Javier Angulo, Francisco J López, Ramón de La Iglesia, Jesús Romero
PURPOSE: The effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in prostate cancer (PCa) patients is not well understood. We evaluated changes in CP after 6 months of medical castration with luteinizing hormone-releasing hormone (LHRH) analogues. METHODS AND MATERIALS: We performed a prospective, observational, multicenter, open-label study of PCa patients scheduled to receive LHRH analogues for ≥6 months. We assessed 4 domains of CP at baseline and after 6 months of ADT: (1) working memory, assessed with the Wechsler Adult Intelligence Scale III (WAIS III) Digit Span subtest; (2) visual memory, assessed with an ad hoc visual memory test; (3) visuospatial ability, assessed with the Judgment of Line Orientation test and Mental Rotation of Three-Dimensional Objects test; and (4) nonverbal analytical reasoning, assessed with the WAIS III Matrix Reasoning test...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28581398/ascende-rt-an-analysis-of-health-related-quality-of-life-for-a-randomized-trial-comparing-low-dose-rate-brachytherapy-boost-with-dose-escalated-external-beam-boost-for-high-and-intermediate-risk-prostate-cancer
#20
Sree Rodda, W James Morris, Jeremy Hamm, Graeme Duncan
PURPOSE: To report the patient-reported health-related quality of life (HR-QoL) outcomes for a multicenter randomized trial evaluating the safety and efficacy of 2 different techniques for dose escalation. METHODS AND MATERIALS: A total of 357 men with intermediate- and high-risk prostate cancer were stratified by risk group and randomized (1:1) to either a dose-escalated external beam (DE-EBRT) boost (n=177) or a low-dose-rate prostate brachytherapy (LDR-PB) boost (n=180) as part of combined modality therapy...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
104014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"